Total: $1,956.83M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
Acusphere Inc. (ACUS) |
Registered direct offering |
7.7U |
$20 |
Acusphere raised $20M, selling 7.7M units at $2.60 each; each unit consists of one share and one warrant to purchase 0.4 shares of common stock at $3.10 each (6/12) |
Amarin Corp. plc (UK; AMRN) |
Private placement of common stock and warrants |
6.16S and W for 0.62S |
$3.7 |
Amarin raised $3.7M pricing 6.16M shares at 60 cents each and granting warrants to buy 0.62M shares at an exercise price of 72 cents per share (6/4) |
AMDL Inc. (AMEX:ADL) |
Private placement of common stock and warrants |
0.587S and W for 0.294S |
$1.54 |
AMDL raised $1.54M in a second closing, bringing the total raised to $5.3M; the first closing was completed in May (6/7) |
Amylin Pharmaceuticals Inc. (AMLN) |
Private placement of convertible senior notes |
N/A |
$575 |
Amylin offered $500M in notes due 2014; purchasers also bought $75M more notes, exercising an overallotment option (6/6) |
Athersys Inc. (merged with BTHC VI Inc.; OTC BB:BTVI) |
Private placement of common stock and warrants |
13S and W |
$65 |
Athersys raised $65M through the financing led by Radius Ventures and including OrbiMed Advisors, RA Capital Management, Accipiter Capital Management LLC, Hambrecht & Quist Capital Management LLC, MPM BioEquities and Pappas Ventures (6/11) |
Auxilium Pharmaceuticals Inc. (AUXL) |
Private placement of common stock |
3.6S |
$52.2 |
Auxilium raised $49.9M net, selling 3.6M shares at $14.50 each (6/8) |
Barrier Therapeutics Inc. (BTRX) |
Senior secured credit facility |
N/A |
$12 |
Barrier received the funds from Merrill Lynch Capital (6/29) |
BioInvent International AB (Sweden; SSE:BINV) |
Private placement |
8.5S |
SEK125 |
BioInvent is raising $17.8M by issuing 8.5M new shares to four Swedish investors, Nordea Fonder, Tredje AP-fonden, Catella Healthcare and Handelsbanken Fonder (6/20)** |
BioSante Pharmaceuticals Inc. (AMEX:BPA) |
Private placement of common stock |
0.4S and 0.076W |
$1.8 |
BioSante raised a total of $18.3M in a private placement of 3.1M shares at $6 each, and warrants to purchase 763,750 shares at $8 per share; Rodman & Renshaw LLC served as lead placement agent, with Oppenheimer & Co. Inc. acting as an additional placement agent (6/14) |
Bioxel Pharma Inc. (Canada; CDNX:BIP) |
Private placement of units |
N/A |
C$8 |
Bioxel entered an engagement letter with Paradigm Capital to raise $7.5M (6/28) |
Ceapro Inc. (Canada; CDNX:CZO) |
Private placement of common stock and warrants |
8.7S and 4.3W |
$2.7 |
Ceapro raised $2.7M issuing 8.7M shares and 4.3M warrants; Northern Securities Inc. acted as lead agent (6/28) |
Curalogic A/S (Denmark; CSE:CUR-N) |
Private placement of common stock |
18S |
DKK306 ($55.3) |
Curalogic raised $55.3M by issuing 18M shares at DKK17 each; it could take in another DKK34M if an overallotment option is exercised (6/27)** |
Dendreon Corp. (DNDN) |
Private placement of convertible senior subordinated notes |
N/A |
$75 |
Dendreon is offering $75M in notes due 2014 (6/4) |
EpiCept Corp. (EPCT) |
Private placement of common stock and warrants |
5.1S and W for 2.56S |
$10 |
EpiCept is raising $10M selling 5.1M shares at $1.95 each, and five-year warrants to buy 2.56M shares at $2.93 per share (6/29) |
ExonHit Therapeutics SA (France; PK:EXHTF) |
Private placement of common stock |
0.4S |
€3.4 |
ExonHit issued 400,000 new shares following the exercise of a tranche of the Paceo line signed between the company and Societe Generale Corporate & Investment Banking in October (6/1) |
IDM Pharma Inc. (IDMI) |
Private placement of common stock and warrants |
7.1S and W for 2.4S |
$25 |
IDM is raising $25M in an offering of common stock and warrants at $3.50 per unit; Rodman & Renshaw is the sole placement agent (6/21) |
Integra Life-Sciences Holdings Corp. (IART) |
Private placement of senior convertible notes |
N/A |
$300 |
Integra priced a private offering of $150M in 2.75% senior convertible notes due in 2010 and $150M in 2.375% senior convertible notes due in 2012 (6/6) |
ISTA Pharmaceuticals Inc. (ISTA) |
Private placement of common stock |
5.25S |
$36.75 |
ISTA is raising $36.75M placing 5.25M shares with institutional investors for $7 each; Lehman Brothers is lead placement agent; other agents are Lazard Freres & Co. LLC, Susquehanna Financial Group LLLP and Thomas Weisel Partners LLC |
Lexicon Pharmaceuticals Inc. (LXRX) |
Private placements |
W for 16.5S |
$265 |
Lexicon raised $205M through the sale of warrants to buy 16.5M shares for $3.09 each and the sale of 34.3M shares at $4.50 each through a deal with Invus Group LLC; it raised an additional $60M through a $45M investment by Symphony Capital Partners LP in a new company - Symphony Icon Inc. - and through a $15M equity investment (6/18) |
Med BioGene Inc. (Canada; CDNX:MBI) |
Private placement of units |
N/A |
$3.18 |
Med BioGene raised the money through two tranches; the second tranche involved 677,500 units at C45 cents each (6/18) |
Memory Pharmaceuticals Corp. (MEMY) |
Private placement |
N/A |
$11 |
Memory entered a definitive agreement to sell up to $6M, principally to the Stanley Medical Research Institute; the company also has a loan agreement with Hercules Technology Growth Capital Inc. for an extra $5M (6/19) |
MicroIslet Inc. (OTC BB:MIIS) |
Private placement of stock and warrants |
2.6S and W for 1.3S |
$1 |
MicroIslet raised $1M through the sale of stock and warrants to accredited investors (6/21) |
Micromet Inc. (MITI) |
Private placement of stock and warrants |
9.2S and W for 4.6S |
$25 |
Micromet raised $25M through a placement with institutional investors; RBC Capital Markets is lead placement agent and C.E. Unterberg, Towbin is co-agent (6/20) |
NeoGenomics Inc. (OTC BB:NGNM) |
Private placement of common stock |
2.7S |
$4 |
NeoGenomics raised $4M through the sale of 2.7M shares at $1.50 each; Noble Financial Group acted as the placement agent (6/7) |
Northwest Biotherapeutics Inc. (OTC BB:NWBT) |
Private placement of common stock |
15.79S |
£15 |
Northwest placed 15.79M shares with foreign institutional investors (6/18) |
Nuvo Research Inc. (Canada; TSX:NRI) |
Private placement of units |
100U |
C$20 |
Nuvo Research raised $18.7M placing 100M units at C20 cents per unit (6/22) |
Ortec International Inc. (PK:OTCI) |
Private placement of Series A convertible preferred stock |
N/A |
$8.7 |
Ortec raised $8.7M, placing 580 shares of preferred stock at $10,000 per share, $2.7M in bridge notes converted to 349 shares of preferred stock and warrants, and $0.2M in bridge notes repaid (6/21) |
Osiris Therapeutics Inc. (OSIR) |
Private placement of common stock |
1.8S |
$20 |
Osiris issued nearly 1.8M shares priced at $11.38 each; Peter Friedli, owner and president of Friedli Corporate Finance led the placement and was followed by New Venturetec Inc. (6/7) |
Osteologix Inc. (OTC BB:OLGX) |
Private placement of common stock and warrants |
3.8S and 1.9W |
$5 |
Osteologix closed a $5M financing in which it sold 3.8M shares and 1.9M warrants (6/7) |
Panacos Pharmaceuticals Inc. (PANC) |
Term loan agreement |
N/A |
$10 |
Panacos closed the agreement with Hercules Technology Growth Capital Inc., receiving $10M immediately; it will draw the remaining $10M by Sept. 30 (6/29) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Private placement of common stock |
30S |
$22.5 |
Peregrine is raising $22.5M issuing 30M shares at 75 cents each; Rodman & Renshaw LLC was placement agent (6/29) |
Progen Pharmaceuticals Ltd. (Australia; PGLA; ASX:PGL) |
Entitlements offer |
N/A |
A$34.1 |
Progen offered entitlements that involved the issue of one share, worth A$5.74 to ASX-listed shareholders, and $4.75 to NASDAQ-listed shareholders (6/21) |
Proteome Sciences plc (UK; LSE:PRM) |
Loan facility |
N/A |
Company's CEO, C.D.J. Pearce increased an existing loan facility from £4M to £6M ($12M) (6/29) |
|
Resverlogix Corp. (Canada; TSX:RVX) |
Bought-deal private placement |
Notes convertible into 1.5S |
$25 |
Resverlogix sold $25M in 8% secured convertible promissory notes, which would be convertible into about 1.5M common shares and accompanying warrants to purchase 530,000 shares at C$20.63 per share (6/5) |
Targeted Genetics Corp. (TGEN) |
Private placement of common stock |
6.7S |
$19.5 |
Targeted Genetics raised $19.5M placing 6.7M shares at $2.91 each; Rodman & Renshaw LLC acted as placement agent (6/22) |
TopoTarget A/S (Denmark; CSE:TOPO) |
Private placement of common stock |
12S |
DKK360 |
TopoTarget raised $65.1M by issuing 12M shares at DKK30 per share (6/27)** |
Transgene SA (France; PARIS: TNG) |
Private placement of common stock |
4.77S |
€87 |
Transgene placed 4.77M new shares at $24.49 each; lead underwriter is Bryan Garnier & Co. (6/20)** |
WaferGen Biosystems Inc. (OTC BB:WGBS) |
Private placement of common stock and warrants |
N/A |
$12 |
WaferGen completed a $12M private placement of common stock and warrants; Rodman & Renshaw LLC acted as exclusive placement agent (6/6) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange | ||||
@ Refers to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | ||||
